Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Más filtros

Medicinas Complementárias
Métodos Terapéuticos y Terapias MTCI
Tipo del documento
Intervalo de año de publicación
1.
Drugs ; 79(Suppl 1): 17-21, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30706423

RESUMEN

Neuropathology of hepatic encephalopathy (HE) in cirrhosis is primarily astroglial in nature characterized by Alzheimer type 2 astrocytosis together with activation of microglia indicative of neuroinflammation. Focal loss of neurons may also occur in the basal ganglia, thalamus and cerebellum. Pathophysiology of HE in cirrhosis is multifactorial, involving brain accumulation of ammonia and manganese, systemic and central inflammation, nutritional/metabolic factors and activation of the GABAergic neurotransmitter system. Neuroimaging and spectroscopic techniques reveal early deactivation of the anterior cingulate cortex in parallel with neuropsychological impairment. T1-weighted MR signal hyperintensities in basal ganglia resulting from manganese lead to a novel entity, 'Parkinsonism in cirrhosis'. Elucidation of the pathophysiological mechanisms has resulted in novel therapeutic approaches to HE aimed at reduction of brain ammonia, reduction of systemic and central inflammation, and reduction of GABAergic tone via the discovery of antagonists of the neurosteroid-modulatory site on the GABA receptor complex.


Asunto(s)
Encefalopatía Hepática/fisiopatología , Cirrosis Hepática/fisiopatología , Amoníaco/metabolismo , Ganglios Basales/fisiopatología , Cerebelo/fisiopatología , Encefalopatía Hepática/tratamiento farmacológico , Encefalopatía Hepática/metabolismo , Humanos , Inflamación/fisiopatología , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Manganeso/metabolismo , Neurotransmisores/antagonistas & inhibidores , Tálamo/fisiopatología , Ácido gamma-Aminobutírico/metabolismo
2.
Cardiovasc Interv Ther ; 33(2): 116-124, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28110424

RESUMEN

We investigated the effects of caffeine intake on fractional flow reserve (FFR) values measured using intravenous adenosine triphosphate (ATP) before cardiac catheterization. Caffeine is a competitive antagonist for adenosine receptors; however, it is unclear whether this antagonism affects FFR values. Patients were evenly randomized into 2 groups preceding the FFR study. In the caffeine group (n = 15), participants were given coffee containing 222 mg of caffeine 2 h before the catheterization. In the non-caffeine group (n = 15), participants were instructed not to take any caffeine-containing drinks or foods for at least 12 h before the catheterization. FFR was performed in patients with more than intermediate coronary stenosis using the intravenous infusion of ATP at 140 µg/kg/min (normal dose) and 170 µg/kg/min (high dose), and the intracoronary infusion of papaverine. FFR was followed for 30 s after maximal hyperemia. In the non-caffeine group, the FFR values measured with ATP infusion were not significantly different from those measured with papaverine infusion. However, in the caffeine group, the FFR values were significantly higher after ATP infusion than after papaverine infusion (P = 0.002 and P = 0.007, at normal and high dose ATP vs. papaverine, respectively). FFR values with ATP infusion were significantly increased 30 s after maximal hyperemia (P = 0.001 and P < 0.001 for normal and high dose ATP, respectively). The stability of the FFR values using papaverine showed no significant difference between the 2 groups. Caffeine intake before the FFR study affected FFR values and their stability. These effects could not be reversed by an increased ATP dose.


Asunto(s)
Adenosina Trifosfato/farmacología , Angina de Pecho/fisiopatología , Cafeína/farmacología , Estenosis Coronaria/fisiopatología , Reserva del Flujo Fraccional Miocárdico/efectos de los fármacos , Neurotransmisores/farmacología , Adenosina Trifosfato/administración & dosificación , Adenosina Trifosfato/antagonistas & inhibidores , Anciano , Angina de Pecho/etiología , Cateterismo Cardíaco , Café , Angiografía Coronaria , Estenosis Coronaria/diagnóstico por imagen , Femenino , Reserva del Flujo Fraccional Miocárdico/fisiología , Hemodinámica , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Neurotransmisores/administración & dosificación , Neurotransmisores/antagonistas & inhibidores , Papaverina/administración & dosificación , Papaverina/farmacología , Estudios Prospectivos , Vasodilatadores/administración & dosificación , Vasodilatadores/antagonistas & inhibidores , Vasodilatadores/farmacología
3.
Int J Med Mushrooms ; 19(6): 499-507, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29199560

RESUMEN

Hericium erinaceus is well known for the neurotrophic effect it confers by promoting nerve growth factor biosynthesis. We discovered a novel bioactivity of H. erinaceus in its ability to suppress adenosine triphosphate (ATP)-induced calcium signaling in neuronal PC12 cells. ATP, known primarily as a neurotransmitter, also acts on purinoceptors (P2 purinergic receptor [P2R]) to generate the cellular calcium signaling and secretion that mediate P2R physiological manifestations, including pain. Chronic pain reduces quality of life. However, constant analgesic administration can cause liver and kidney injury, as well as loss of the analgesic effect because of desensitization. In this study we investigated the analgesic potential of H. erinaceus through measurements of ATP-induced Ca2+ signaling in cell lines and observation of pain behaviors in mice. In P2R-coupled Ca2+ signaling measurements, extracts of H. erinaceus mycelia (HEEs) blocked ATP-induced Ca2+ signaling in both rat PC12 cells and human HOS cells. HEEs completely blocked ATP-induced Ca2+ signaling in human HOS cells, suggesting that this effect of HEEs is exerted through the P2R subtypes present in HOS cells, which include the P2X4, P2X7, P2Y2, and P2Y4 subtypes. In observations of animal behavior during pain, HEEs significantly reduced heat-induced pain, including postponing both the tail-flick response to heat stimulation and the paw-lifting response to a hot plate. This study demonstrates novel characteristics of H. erinaceus in reducing nociceptive behavior and blocking the functional activity of P2R. Further studies are required to verify this linkage and its molecular mechanisms.


Asunto(s)
Adenosina Trifosfato/metabolismo , Basidiomycota/química , Productos Biológicos/farmacología , Señalización del Calcio/efectos de los fármacos , Neurotransmisores/metabolismo , Dolor/tratamiento farmacológico , Adenosina Trifosfato/antagonistas & inhibidores , Animales , Micelio/química , Factor de Crecimiento Nervioso/efectos de los fármacos , Factor de Crecimiento Nervioso/metabolismo , Neurotransmisores/antagonistas & inhibidores , Células PC12 , Calidad de Vida , Ratas , Receptores Purinérgicos/efectos de los fármacos , Receptores Purinérgicos/metabolismo
4.
Molecules ; 22(7)2017 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-28714881

RESUMEN

The actions of many drugs involve enzyme inhibition. This is exemplified by the inhibitors of monoamine oxidases (MAO) and the cholinsterases (ChE) that have been used for several pharmacological purposes. This review describes key principles and approaches for the reliable determination of enzyme activities and inhibition as well as some of the methods that are in current use for such studies with these two enzymes. Their applicability and potential pitfalls arising from their inappropriate use are discussed. Since inhibitor potency is frequently assessed in terms of the quantity necessary to give 50% inhibition (the IC50 value), the relationships between this and the mode of inhibition is also considered, in terms of the misleading information that it may provide. Incorporation of more than one functionality into the same molecule to give a multi-target-directed ligands (MTDLs) requires careful assessment to ensure that the specific target effects are not significantly altered and that the kinetic behavior remains as favourable with the MTDL as it does with the individual components. Such factors will be considered in terms of recently developed MTDLs that combine MAO and ChE inhibitory functions.


Asunto(s)
Inhibidores de la Colinesterasa/química , Inhibidores de la Colinesterasa/farmacología , Descubrimiento de Drogas , Inhibidores de la Monoaminooxidasa/química , Inhibidores de la Monoaminooxidasa/farmacología , Animales , Inhibidores de la Colinesterasa/uso terapéutico , Colinesterasas/química , Colinesterasas/metabolismo , Simulación por Computador , Descubrimiento de Drogas/métodos , Evaluación Preclínica de Medicamentos , Activación Enzimática/efectos de los fármacos , Humanos , Monoaminooxidasa/química , Monoaminooxidasa/metabolismo , Inhibidores de la Monoaminooxidasa/uso terapéutico , Enfermedades Neurodegenerativas/tratamiento farmacológico , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/metabolismo , Enfermedades Neurodegenerativas/patología , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/metabolismo , Relación Estructura-Actividad
5.
Epilepsy Behav ; 71(Pt B): 124-129, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-25819950

RESUMEN

Here, we describe in generalized epilepsies the alterations of classical neurotransmitters and neuropeptides acting at specific subreceptors. In order to consider a network context rather than one based on focal substrates and in order to make the interaction between neurotransmitters and neuropeptides and their specific subreceptors comprehensible, neural networks in the hippocampus, thalamus, and cerebral cortex are described. In this disease, a neurotransmitter imbalance between dopaminergic and serotonergic neurons and between presynaptic GABAergic neurons (hypoactivity) and glutaminergic neurons (hyperactivity) occurs. Consequently, combined GABAA agonists and NMDA antagonists could furthermore stabilize the neural networks in a multimodal pharmacotherapy. The antiepileptic effect and the mechanisms of action of conventional and recently developed antiepileptic drugs are reviewed. The GASH:Sal animal model can contribute to examine the efficacy of antiepileptic drugs. The issues of whether the interaction of classical neurotransmitters with other subreceptors (5-HT7, metabotropic 5 glutaminergic, A2A adenosine, and alpha nicotinic 7 cholinergic receptors) or whether the administration of agonists/antagonists of neuropeptides might improve the therapeutic effect of antiepileptic drugs should be addressed. This article is part of a Special Issue entitled "Genetic and Reflex Epilepsies, Audiogenic Seizures and Strains: From Experimental Models to the Clinic".


Asunto(s)
Anticonvulsivantes/metabolismo , Epilepsia Generalizada/tratamiento farmacológico , Epilepsia Generalizada/metabolismo , Neuropéptidos/metabolismo , Neurotransmisores/metabolismo , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Modelos Animales de Enfermedad , Neuronas GABAérgicas/efectos de los fármacos , Neuronas GABAérgicas/metabolismo , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Red Nerviosa/efectos de los fármacos , Red Nerviosa/metabolismo , Neuropéptidos/agonistas , Neuropéptidos/antagonistas & inhibidores , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Tálamo/efectos de los fármacos , Tálamo/metabolismo , Resultado del Tratamiento
6.
Neurocrit Care ; 24(3): 459-71, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26561305

RESUMEN

INTRODUCTION: Propofol exhibits neuroprotective effects mediated by the inhibition of excitatory amino acid (EAA) neurotransmitter release and potentiation of inhibitory amino acid (IAA) neurotransmitters. To our knowledge, this is the first study to investigate the effects of propofol on the EAA and IAA balance in neurogenic pulmonary edema (NPE). METHODS: Sixty male Wistar rats were randomized to Sham, NPE, Low-dose propofol, and High-dose propofol groups. NPE was induced via rapid injection of autologous blood (0.5 ml) into the cisterna magna. The Low- and High-dose propofol groups were pretreated with boluses of 2 and 5 mg kg(-1), respectively, prior to blood injection, followed by continuous propofol infusion at 6 and 15 mg kg(-1) h(-1), respectively. The mean arterial pressure (MAP), heart rate, intracranial pressure (ICP), peak inspiratory pressure (PIP), and arterial blood gases were continuously recorded. After 2 h, the lung wet-to-dry weight ratio, total protein concentration in the bronchoalveolar lavage fluid (BALF), brain water content, cortical EAA and IAA levels, chest X-ray, and histological staining of lung sections were evaluated. RESULTS: Blood injections into the cisterna magna induced NPE and hemodynamic changes. Propofol alleviated the increases in the MAP, ICP, and PIP, improved oxygenation and histopathological changes, ameliorated pulmonary and cerebral edema, increased the IAA brain levels, and decreased the ratio of Glu to γ-aminobutyric acid. CONCLUSIONS: The current findings suggest that propofol improves NPE likely via IAA accumulation and the regulation of EAA and IAA balance, which may represent an effective treatment for NPE.


Asunto(s)
Edema Encefálico/tratamiento farmacológico , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Fármacos Neuroprotectores/farmacología , Neurotransmisores/metabolismo , Propofol/farmacología , Edema Pulmonar/tratamiento farmacológico , Hemorragia Subaracnoidea/complicaciones , Animales , Edema Encefálico/etiología , Modelos Animales de Enfermedad , Aminoácidos Excitadores/antagonistas & inhibidores , Ácido Glutámico/efectos de los fármacos , Masculino , Fármacos Neuroprotectores/administración & dosificación , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Propofol/administración & dosificación , Edema Pulmonar/etiología , Ratas , Ratas Wistar , Ácido gamma-Aminobutírico/efectos de los fármacos
7.
Nihon Rinsho ; 73(6): 1023-30, 2015 Jun.
Artículo en Japonés | MEDLINE | ID: mdl-26065136

RESUMEN

Orexin A and orexin B are hypothalamic neuropeptides that were discovered in 1998. Several studies suggested that orexin deficiency causes narcolepsy in humans and other mammalian species, highlighting roles of this hypothalamic neuropeptide in the regulation of sleep and wakefulness. The orexin system regulates sleep and wakefulness through interactions with systems that regulate emotion, reward and energy homeostasis. This system regulates sleep and wakefulness to occur at appropriate times that are in accordance with our internal and external environments. Recent findings have brought about the possibility of novel therapies targeting orexin system for sleep disorder including insomnia and narcolepsy-cataplexy. In this review, I will discuss the current understanding of the integrative physiology and clinical perspectives of the orexin system.


Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/farmacología , Neuropéptidos/farmacología , Neurotransmisores/antagonistas & inhibidores , Antagonistas de los Receptores de Orexina , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Sueño/efectos de los fármacos , Vigilia/efectos de los fármacos , Humanos , Hipotálamo/efectos de los fármacos , Orexinas , Sueño/fisiología , Vigilia/fisiología
8.
Neuroendocrinology ; 98(3): 233-41, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24080898

RESUMEN

Clusterin is a sulfated glycoprotein abundantly expressed in the pituitary gland and hypothalamus of mammals. However, its physiological role in neuroendocrine function is largely unknown. In the present study, we investigated the effects of intracerebroventricular (ICV) administration of clusterin on plasma pituitary hormone levels in normal rats. Single ICV injection of clusterin provoked neurohormonal changes seen under acute stress condition: increased plasma adrenocorticotropic hormone (ACTH), corticosterone, GH and prolactin levels and decreased LH and FSH levels. Consistently, hypothalamic and pituitary clusterin expression levels were upregulated following a restraint stress, suggesting an involvement of endogenous clusterin in stress-induced neurohormonal changes. In the pituitary intermediate lobe, clusterin was coexpressed with proopiomelanocortin (POMC), a precursor of ACTH. Treatment of clusterin in POMC expressing AtT-20 pituitary cells increased basal and corticotropin-releasing hormone (CRH)-stimulated POMC promoter activities and intracellular cAMP levels. Furthermore, clusterin treatment triggered ACTH secretion from AtT-20 cells in a CRH-dependent manner, indicating that increased clusterin under stressful conditions may augment CRH-stimulated ACTH production and release. In summary, hypothalamic and pituitary clusterin may function as a modulator of neurohormonal responses under stressful conditions.


Asunto(s)
Clusterina/fisiología , Hipotálamo/metabolismo , Neurotransmisores/biosíntesis , Hipófisis/metabolismo , Hormona Adrenocorticotrópica/antagonistas & inhibidores , Hormona Adrenocorticotrópica/biosíntesis , Hormona Adrenocorticotrópica/metabolismo , Animales , Clusterina/administración & dosificación , Clusterina/sangre , Hipotálamo/efectos de los fármacos , Inyecciones Intraventriculares , Masculino , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/metabolismo , Hipófisis/efectos de los fármacos , Proopiomelanocortina/antagonistas & inhibidores , Proopiomelanocortina/biosíntesis , Proopiomelanocortina/metabolismo , Ratas , Ratas Sprague-Dawley , Estrés Psicológico/sangre , Estrés Psicológico/prevención & control , Estrés Psicológico/psicología , Regulación hacia Arriba/fisiología
9.
Cent Nerv Syst Agents Med Chem ; 12(4): 315-28, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23270323

RESUMEN

The nervous system is a primary target for animal venoms as the impairment of its function results in the fast and efficient immobilization or death of a prey. There are numerous evidences about effects of crude snake venoms or isolated toxins on peripheral nervous system. However, the data on their interactions with the central nervous system (CNS) are not abundant, as the blood-brain barrier (BBB) impedes penetration of these compounds into brain. This updated review presents the data about interaction of snake venom polypeptides with CNS. Such data will be described according to three main modes of interactions: - Direct in vivo interaction of CNS with venom polypeptides either capable to penetrate BBB or injected into the brain. - In vitro interactions of cell or sub-cellular fractions of CNS with crude venoms or purified toxins. - Indirect effects of snake venoms or their components on functioning of CNS under different conditions. Although the venom components penetrating BBB are not numerous, they seem to be the most suitable candidates for the leads in drug design. The compounds with other modes of action are more abundant and better studied, but the lack of the data about their ability to penetrate BBB may substantially aggravate the potentials for their medical perspectives. Nevertheless, many such compounds are used for research of CNS in vitro. These investigations may give invaluable information for understanding the molecular basis of CNS diseases and thus lay the basis for targeted drug design. This aspect also will be outlined in the review.


Asunto(s)
Sistema Nervioso Central/efectos de los fármacos , Neurotoxinas/farmacología , Péptidos/farmacología , Venenos de Serpiente/farmacología , Analgésicos/aislamiento & purificación , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Barrera Hematoencefálica , Sistema Nervioso Central/citología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Intraventriculares , Ratones , Factores de Crecimiento Nervioso/farmacología , Neuronas/efectos de los fármacos , Neuronas/fisiología , Neurotoxinas/química , Neurotoxinas/clasificación , Neurotoxinas/aislamiento & purificación , Neurotoxinas/farmacocinética , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Manejo del Dolor , Percepción del Dolor/efectos de los fármacos , Péptidos/química , Péptidos/aislamiento & purificación , Péptidos/farmacocinética , Péptidos/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto , Venenos de Serpiente/química , Venenos de Serpiente/farmacocinética , Venenos de Serpiente/uso terapéutico , Serpientes , Fracciones Subcelulares/efectos de los fármacos
10.
Bol. venez. infectol ; 22(1): 48-52, ene.-jun. 2011. tab
Artículo en Español | LILACS | ID: lil-721082

RESUMEN

La meningitis bacteriana continúa siendo una enfermedad potencialmente fatal, especialmente en países en vías de desarrollo. Los aminoácidos excitatorios están fuertemente implicados en la patogénesis del daño neuronal en meningitis bacteriana. El objetivo fue medir niveles de glutamato, GABA, glicina y taurina en liquido cefalorraquídeo y correlacionarlos con el grado de severidad, complicaciones y secuelas. Estudio prospectivo en 31 pacientes con meningitis bacteriana y 10 pacientes con líquido cefalorraquídeo normal (control), con edades de 1 mes - 13 años de edad. El análisis de aminoácidos se realizó al ingreso y al tercer día mediante cromatografía líquida de alta presión. De los 31 pacientes que ingresaron al estudio 64,5 % fueron de género femenino, 13 lactantes, 8 preescolares y 10 escolares. El promedio de aminoácidos en los niños con meningitis fue más alto que en el grupo control (P<0,01). El glutamato disminuyó significativamente en pacientes con hidrocefalia. El GABA está disminuido en pacientes con parálisis cerebral y la taurina está disminuida en higroma y aumentada en lesión de pares craneales, trastornos de la conducta e hipoacusia. Los cambios en los niveles de aminoácidos en líquido cefalorraquídeo refleja el estado patológico y severidad del daño cerebral. Este estudio provee información del eventual papel de la inmunomodulación y posible uso de antagonistas de aminoácidos excitatorios, con efecto neuroprotector, en el tratamiento de meninigitis bacteriana e indica que esta clase de molécula neurotóxica puede represetar un importante blanco en la terapia adyuvante para meningitis bacteriana.


Bacterial meningitis rmains a potentially fatal disease, especially in developing countries. Exitatory amino acids are strongly implicated in the pathogenesis of neuronal damage in bacterial meningitis. To measure levels of glutamate, GABA, glycine and taurine in cerebroespinal fluid and correlate with the degree of severity, complications and sequelae. Prospective study in 31 patients with bacterial meningitis and 10 patients with normal cerebrospinal fluid (control), aged 1 month - 13 years old. Amino acid analysis was performed on admission and on the third day using high pressure liquid chromatography. Of the 31 patients entering the study 64.5 % were females, 13 infants, 8 preschoolers and 10 elementary school students. The average number of amino acids in children with meningitis was higher than in the control group (P<0.01). Glutamate levels significantly decreased in patients with hydrocephalus. GABA levels decreased in patients with cerebral pasly, and taurine diminished in hygroma, and increased in cranial nerve injury, eating disorders and hearing loss. Changes in amino acid levels in cerebrospinal fluid reflect pathological state and severity of brain damage. This study provides information on the possible role of immunomudulation and possible use of excitatory amino acid antogonists with neuroprotective effects in the treatment of bacterial meningitis, indicating that this class of neurotoxic molecules may represent important target in adjuvant therapy for bacterial meningitis.


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Antagonistas de Aminoácidos Excitadores/farmacología , Meningitis Bacterianas/patología , Neurotransmisores/administración & dosificación , Neurotransmisores/antagonistas & inhibidores , Ácido Glutámico/administración & dosificación , Ácido Glutámico/uso terapéutico , Agonistas de Aminoácidos Excitadores
11.
J Neurophysiol ; 103(4): 1937-53, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20107121

RESUMEN

This study presents a novel mathematical modeling framework that is uniquely suited to investigating the structure and dynamics of the sleep-wake regulatory network in the brain stem and hypothalamus. It is based on a population firing rate model formalism that is modified to explicitly include concentration levels of neurotransmitters released to postsynaptic populations. Using this framework, interactions among primary brain stem and hypothalamic neuronal nuclei involved in rat sleep-wake regulation are modeled. The model network captures realistic rat polyphasic sleep-wake behavior consisting of wake, rapid eye movement (REM) sleep, and non-REM (NREM) sleep states. Network dynamics include a cyclic pattern of NREM sleep, REM sleep, and wake states that is disrupted by simulated variability of neurotransmitter release and external noise to the network. Explicit modeling of neurotransmitter concentrations allows for simulations of microinjections of neurotransmitter agonists and antagonists into a key wake-promoting population, the locus coeruleus (LC). Effects of these simulated microinjections on sleep-wake states are tracked and compared with experimental observations. Agonist/antagonist pairs, which are presumed to have opposing effects on LC activity, do not generally induce opposing effects on sleep-wake patterning because of multiple mechanisms for LC activation in the network. Also, different agents, which are presumed to have parallel effects on LC activity, do not induce parallel effects on sleep-wake patterning because of differences in the state dependence or independence of agonist and antagonist action. These simulation results highlight the utility of formal mathematical modeling for constraining conceptual models of the sleep-wake regulatory network.


Asunto(s)
Conducta Animal/efectos de los fármacos , Modelos Biológicos , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/farmacología , Sueño/efectos de los fármacos , Vigilia/efectos de los fármacos , Animales , Conducta Animal/fisiología , Tronco Encefálico/efectos de los fármacos , Tronco Encefálico/fisiología , Hipotálamo/efectos de los fármacos , Hipotálamo/fisiología , Locus Coeruleus/efectos de los fármacos , Locus Coeruleus/fisiología , Microinyecciones , Modelos Animales , Modelos Teóricos , Neurotransmisores/administración & dosificación , Ratas , Sueño/fisiología , Sueño REM/efectos de los fármacos , Sueño REM/fisiología , Vigilia/fisiología
12.
Exp Cell Res ; 314(14): 2603-17, 2008 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-18586028

RESUMEN

We have investigated the role of N-methyl-d-aspartate receptors (NMDARs) and gamma-aminobutyric acid receptors type A (GABA(A)Rs) at an early stage of P19 neuronal differentiation. The subunit expression was profiled in 24-hour intervals with RT-PCR and functionality of the receptors was verified via fluo-3 imaging of Ca(2+) dynamics in the immature P19 neurons showing that both NMDA and GABA excite neuronal bodies, but only polyamine-site sensitive NMDAR stimulation leads to enhanced Ca(2+) signaling in the growth cones. Inhibition of NR1/NR2B NMDARs by 1 muM ifenprodil severely impaired P19 neurite extension and fasciculation, and this negative effect was fully reversible by polyamine addition. In contrast, GABA(A)R antagonism by a high dose of 200 microM bicuculline had no observable effect on P19 neuronal differentiation and fasciculation. Except for the differential NMDAR and GABA(A)R profiles of Ca(2+) signaling within the immature P19 neurons, we have also shown that inhibition of NR1/NR2B NMDARs strongly decreased mRNA level of NCAM-180, which has been previously implicated as a regulator of neuronal growth cone protrusion and neurite extension. Our data thus suggest a critical role of NR1/NR2B NMDARs during the process of neuritogenesis and fasciculation of P19 neurons via differential control of local growth cone Ca(2+) surges and NCAM-180 signaling.


Asunto(s)
Diferenciación Celular , Neuritas/fisiología , Poliaminas/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Animales , Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Línea Celular , Maleato de Dizocilpina/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Conos de Crecimiento/efectos de los fármacos , Conos de Crecimiento/metabolismo , Ratones , Neuritas/efectos de los fármacos , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Piperidinas/farmacología , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Receptores de GABA-A/genética , Receptores de GABA-A/metabolismo , Receptores de N-Metil-D-Aspartato/genética
13.
Zhongguo Zhong Yao Za Zhi ; 33(23): 2830-3, 2008 Dec.
Artículo en Chino | MEDLINE | ID: mdl-19260324

RESUMEN

OBJECTIVE: To study the effects of Tianwang Buxinwan decoction on the contents of amino acids neurotransmitters in corpus striatum of rats to implicate the mechanism of Tianwang Buxinwan promoting and Improving sleeping. METHOD: Contents of two amino acids neurotransmitters in corpus striatum of rats were prepared by microdialysis technology and were determined by HPLC which involved pre-column derivation with orthophthaladehyde, recersed-phase gradient elution and fluorescence detection. RESULT: In the experimental separation condition, Tianwang Buxinwan seemed do not influence three kinds of contents of amino acids neurotransmiters (glutamic acid, glycin, aspartic acid), but TBW seemed increase the content of gamma-GABA in corpus striatum of rats. CONCLUSION: The effects of Tianwang Buxinwan to relieve uneasiness may relate with the inhibitory amino acids gamma-GABA. Tianwang Buxinwan may promote increasing the content of gamma-GABA. This discovery may be helpful for the deep study of related mechanism of Tianwang Buxinwan.


Asunto(s)
Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Medicamentos Herbarios Chinos/administración & dosificación , Neurotransmisores/antagonistas & inhibidores , Animales , Química Encefálica , Masculino , Microdiálisis , Neurotransmisores/metabolismo , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley
14.
MMW Fortschr Med ; 149(47): 47-8, 2007 Nov 22.
Artículo en Alemán | MEDLINE | ID: mdl-18064816

RESUMEN

In pain therapy we are repeatedly faced with the problem that the available treatment methods are inadequate. For years we have also been using botulinum toxin especially for myofascial pain and chronic headaches. Unfortunately, the assessment of its efficacy in both everyday clinical conditions and in studies is very variable. A final evaluation is not yet possible. Until the results of current studies are available, the use of botulinum toxin should be limited to clinical studies and to particular cases at specialized centres.


Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Dolor/tratamiento farmacológico , Animales , Toxinas Botulínicas Tipo A/efectos adversos , Trastornos de Cefalalgia/tratamiento farmacológico , Humanos , Inyecciones Intramusculares , Síndromes del Dolor Miofascial/tratamiento farmacológico , Neurotransmisores/antagonistas & inhibidores , Umbral del Dolor/efectos de los fármacos , Resultado del Tratamiento
15.
Pharmacology ; 71(2): 102-6, 2004 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15118349

RESUMEN

In the present study, we aimed to evaluate the effects of PDE V inhibition on NO-mediated relaxation responses in isolated guinea pig trachea. Under the NANC conditions, tracheal preparations were contracted with histamine (100 microm/l). When contraction had reached a plateau, relaxation responses to electrical field stimulation (EFS, 60 V, 0.5 ms, 5-10 Hz) were determined before and after incubation of the tracheal ring with L-NAME (1 mmol/l), a NO synthase inhibitor. L-NAME significantly inhibited the relaxation responses and this inhibitory effect was reversed by L-arginine (1 mmol/l), a precursor of NO, but was not affected by D-arginine. In addition, cumulative application of the NO donors, 3-morpholino-sydnonimine (SIN-1) and sodium nitroprusside (SNP), caused concentration-dependent relaxation of tissues precontracted with histamine. The selective PDE type V inhibitor zaprinast at EC50 concentration (30 micromol/l) significantly potentiated EFS-induced NANC relaxations and relaxant responses to SIN-1 and SNP. In conclusion, these data support the hypothesis that NO is a mediator of NANC relaxations of guinea pig tracheal rings and PDE V inhibition potentiates NO-mediated relaxation.


Asunto(s)
Molsidomina/análogos & derivados , Relajación Muscular/efectos de los fármacos , Óxido Nítrico/farmacología , Inhibidores de Fosfodiesterasa/farmacología , Hidrolasas Diéster Fosfóricas/química , Hidrolasas Diéster Fosfóricas/efectos de los fármacos , Tráquea/efectos de los fármacos , 3',5'-GMP Cíclico Fosfodiesterasas , Animales , Arginina/farmacología , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5 , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Estimulación Eléctrica/métodos , Electrodos , Cobayas , Histamina/farmacología , Isomerismo , Masculino , Molsidomina/farmacología , Relajación Muscular/fisiología , Músculo Liso/efectos de los fármacos , Músculo Liso/patología , Músculo Liso/fisiopatología , NG-Nitroarginina Metil Éster/antagonistas & inhibidores , NG-Nitroarginina Metil Éster/farmacología , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/fisiología , Óxido Nítrico/fisiología , Nitroprusiato/farmacología , Hidrolasas Diéster Fosfóricas/farmacología , Purinonas/farmacología , Tráquea/patología , Tráquea/fisiopatología
16.
Prog Neurobiol ; 56(5): 507-40, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9775402

RESUMEN

The basal ganglia have been implicated in a number of important motor functions, in particular in the initiation of motor responses. According to the current model of basal ganglia functions, motor initiation is supposed to be associated with an inhibition of basal ganglia output structures (substantia nigra pars reticulata/entopeduncular nucleus) which, in turn, might be brought about by corresponding striatal activity changes conveyed via direct and indirect intrinsic pathways to the substantia nigra pars reticulata and the entopeduncular nucleus. Rodent studies using neuropharmacological manipulations of basal ganglia transmitter systems by neurotoxins or drugs provide converging evidence that dopamine within the caudate-putamen, but also within extrastriatal basal ganglia nuclei, is involved in motor initiation by modulating the activity of direct and indirect intrinsic pathways. However, the striatal segregation of dopamine D1 and D2 receptors in control of the direct and indirect projection neurons seems not to be maintained throughout the basal ganglia. In dopamine intact animals, striatal glutamate plays a major role in response initiation probably through actions on striatopallidal neurons involving N-methyl-D-aspartate, but not alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. Striatal adenosine might also contribute to movement initiation by acting on adenosine A2A receptors located on striatopallidal neurons. Analysis of two integral parts of the indirect pathway revealed that inactivation of the subthalamic nucleus was found to facilitate response initiation, while inactivation of the globus pallidus resulted in facilitation as well as inhibition of response initiation indicating a complex contribution of this latter nucleus. Glutamate and gamma-amino-butyric acid (GABA) controlling the activity of the substantia nigra pars reticulata could be involved in control of response initiation in a way predicted by the simplified model of basal ganglia functions. In contrast, the role of the entopeduncular nucleus in response initiation and its control through GABA and glutamate is at variance with this hypothesis, suggesting functional differences of the output structures. Taken together, neurochemical systems of the basal ganglia significantly contribute to intact response initiation by mechanisms which are only partly consistent with predictions of the current functional scheme of the basal ganglia. This suggests that a more complex model is required to account for these disparate findings.


Asunto(s)
Ganglios Basales/fisiología , Movimiento/fisiología , Animales , Ganglios Basales/anatomía & histología , Corteza Cerebral/fisiología , Humanos , Modelos Neurológicos , Trastornos del Movimiento/fisiopatología , Neurotransmisores/agonistas , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/fisiología , Desempeño Psicomotor/fisiología , Ratas , Tálamo/fisiología
17.
J Ethnopharmacol ; 57(3): 189-96, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9292412

RESUMEN

Lyophilised decoction (10%) of the leaves of Bridelia atroviridis Muell. Arg. (Euphorbiaceae) was studied in the rat cardiovascular system. In vivo, the extract (15 and 30 mg/kg) caused a decrease of arterial pressure and a decrease of heart rate in an anaesthetized rat (ethylcarbamate 1.2 g/kg). If administrations of Bridelia were repeated (three times) a tachyphylaxie phenomena was observed. After administrations of adrenaline, noradrenaline, acethylcholine and isoprenaline the extract had no effect on the action of these neuromediators on blood pressure. In vitro the extract induced dose-dependent negative inotropic and chronotropic effects in isolated rat heart. It was ineffective in rat aorta preparations. Bridelia seemed to have a direct effect on rat heart. Hypotension is not due to an action on the vessels. The extract did not appear to interact with adrenergic nor cholinergic receptors. However, the extract was able to potentiate barium chloride induced contractions of rat aorta preparations. The extract might act through potential dependent calcium channels.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Corazón/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , Neurotransmisores/antagonistas & inhibidores , Extractos Vegetales/farmacología , Receptores Adrenérgicos/efectos de los fármacos , Receptores Colinérgicos/efectos de los fármacos , Animales , Aorta/efectos de los fármacos , Aorta/metabolismo , Canales de Calcio/efectos de los fármacos , Cardiotónicos/administración & dosificación , Cardiotónicos/farmacología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Hipotensión/inducido químicamente , Técnicas In Vitro , Masculino , Medicina Tradicional , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/toxicidad , Hojas de la Planta , Ratas , Ratas Sprague-Dawley , Taquifilaxis
18.
Am J Physiol ; 266(4 Pt 2): R1287-96, 1994 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7910435

RESUMEN

The putative neurotransmitters in ascending visceral pathways were investigated by recording changes in the response of thalamic neuronal activity evoked by vagal stimulation before and after neurotransmitter antagonist injections into the parabrachial nucleus (PB). Male Wistar rats (n = 39) were anesthetized with chloral hydrate and alpha-chloralose, ventilated, and blood pressure and heart rate were continuously monitored. The left cervical vagus nerve was stimulated to elicit changes in single and multiunit activity in the visceral thalamus. Peristimulus-time histograms of thalamic activity were made before and after 200-nl injections of antagonist or control solution into the PB. Synaptic blockade using cobalt (10 mM) injections into the PB inhibited both the thalamic response evoked by vagal stimulation (86-100%) and the spontaneous firing of thalamic neurons (88-92%). Injections of kynurenate (250 mM) or the N-methyl-D-aspartate (NMDA) antagonist, DL-2-amino-5-phosphonopentanoic acid (AP-5; 200 microM), inhibited (87-94% and 92-100%) the thalamic neuronal response evoked by vagal stimulation. The alpha-adrenergic antagonist, phentolamine (0.1 microM), or the specific alpha 2-adrenergic antagonist, yohimbine (0.1 microM), inhibited the spontaneous firing of thalamic units (42-56% and 64-77%) but had no effect on the vagally evoked response. Bicuculline [gamma-aminobutyric acid (GABA) A-subtype antagonist] significantly enhanced spontaneous thalamic neuronal activity (108-125%) without effect on the vagally evoked response. Atropine (0.1 microM) had no significant effect on either the vagally evoked response or the spontaneous firing of thalamic neurons. These results suggest that the relay of visceral afferent sensory information through the PB is mediated by NMDA receptors and that alpha 2 and GABAA receptors contribute to the tonic activity of ventral basal thalamic neurons receiving visceral input.


Asunto(s)
Neurotransmisores/fisiología , Rombencéfalo/fisiología , Tálamo/fisiología , Vísceras/inervación , Aminoácidos/antagonistas & inhibidores , Animales , Catecolaminas/antagonistas & inhibidores , Cobalto/farmacología , Interacciones Farmacológicas , Estimulación Eléctrica , Antagonistas del GABA , Inyecciones , Masculino , Bulbo Raquídeo/fisiología , Vías Nerviosas/fisiología , Neurotransmisores/antagonistas & inhibidores , Ratas , Ratas Wistar
19.
Brain Res ; 633(1-2): 312-6, 1994 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-7907936

RESUMEN

The effect of excitatory amino acid (EAA) on the release of CRH and AVP--two major neurohumoral activators of the hypothalamic-pituitary-adrenal axis--was studied by in vitro perifusion of hypothalamic organ explants with various concentrations of EAA receptor agonists and antagonists. The agonists L-glutamate (GLU), kainic acid (KAIN) and L-aspartate (ASP) significantly decreased CRH release, while N-methyl-D-aspartate (NMDA) and quisqualic acid (QUIS) did not affect this parameter. AVP release was significantly stimulated by ASP and NMDA, decreased by KAIN and QUIS, and not influenced by GLU. Co-perifusion with equimolar concentrations of ASP and the selective NMDA receptor antagonist D-alpha-aminoadipic acid (aAA) partially diminished the effect of ASP on AVP release, but failed to affect ASP-induced suppression of CRH secretion. The broad-spectrum EAA receptor antagonist kynurenic acid (KYN) completely abolished ASP effects on CRH and AVP release in vitro. The results suggest that EAA transmitters might participate in the regulation of hypothalamic-pituitary-adrenal axis by differentially affecting the release of the two major ACTH secretagogues. In addition, EAA effects on hypothalamic CRH and AVP secretion appear to employ more than one subtype of amino acid receptors.


Asunto(s)
Aminoácidos/farmacología , Arginina Vasopresina/metabolismo , Hormona Liberadora de Corticotropina/metabolismo , Sistema Hipotálamo-Hipofisario/fisiología , Hipotálamo/metabolismo , Neurotransmisores/farmacología , Sistema Hipófiso-Suprarrenal/fisiología , Ácido 2-Aminoadípico/farmacología , Aminoácidos/antagonistas & inhibidores , Animales , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Hipotálamo/efectos de los fármacos , Técnicas In Vitro , Ácido Quinurénico/farmacología , Masculino , Neurotransmisores/antagonistas & inhibidores , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Radioinmunoensayo , Ratas , Ratas Sprague-Dawley
20.
Gen Pharmacol ; 24(4): 983-9, 1993 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7901116

RESUMEN

1. This study examines the effects of methanolic extract (ME) and its main constituent, sorocein A, isolated from the roots of Sorocea bonplandii on agonist-induced contractions in the rat uterus (RU) and in the guinea pig ileum (GPI) in vitro. 2. ME (25-100 micrograms/ml), added to RU for 20 min, caused a graded and parallel shift to the right of bradykinin (BK)-mediated contractions with an apparent pA2 value (-log g/ml) of 5.0 ME caused a rightward shift of the acetylcholine (ACh) and oxytocin-induced contractions associated with a marked depression of their maximal responses. 3. In GPI, ME produced a non-competitive antagonism against BK-induced contraction, while responses to ACh and histamine were shifted to the right in a graded fashion, yielding pA2 values (g/ml) of 5 in both cases. 4. The purified compound sorocein A (15-60 microM) caused a parallel and graded rightward displacement of BK and ACh concentration-response curves in RU with pA2 values (molar basis) of 4.9 and 5.2. 5. Sorocein A also dose-dependently shifted to the right ACh and histamine-mediated contractions in GPI, yielding pA2 values of 5.1 and 4.8, respectively. 6. However, sorocein A antagonized in a non-competitive manner BK-induced contraction in GPI, characterized by a graded displacement to the right of the dose-response curve, and progressive depression of the maximal contraction.


Asunto(s)
Cromanos/farmacología , Íleon/efectos de los fármacos , Extractos Vegetales/farmacología , Contracción Uterina/efectos de los fármacos , Acetilcolina/farmacología , Animales , Bradiquinina/farmacología , Femenino , Cobayas , Histamina/farmacología , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Neurotransmisores/antagonistas & inhibidores , Neurotransmisores/farmacología , Oxitocina/farmacología , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA